MPs join hands to attack ‘derogatory’ cartoon on Ambedkar Two eminent scholars have resigned their positions as advisers to the National Council of Educational Research and Training (NCERT) after a furore in Parliament led Human Resource Development Minister Kapil Sibal to withdraw a book on the Constitution because it contained a cartoon some legislators said was offensive. Yogendra Yadav and Suhas Palshikar, both eminent political scientists, resigned hours after the cartoon provoked...

-The Times of India As part of its mandatory obligation under the United Nations Convention against Corruption (UNCAC), the government has invited expression of interest (EoI) from registered Indian law institutions\firms, academic or Research organizations to undertake the self-evaluation study. Selected agency will be required to complete its works - assessment of compliance of domestic laws\measures vis-a-vis requirements under UNCAC provisions - within 36 weeks. India had ratified the global convention to...

-PTI Study claims more than half of them died in the first 28 days of their life More than 16.8 lakh children under five years died of infectious, but preventable, diseases in India in 2010 and more than half of them could not complete the first month of their life, a new study has claimed. Of the total deaths, 52 per cent, or about 0.875 million, were among the children who died in...

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...